SAN DIEGO, March 25, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer.

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

SAN DIEGO – DexCom has named Jon Coleman as chief commercial officer to oversee the company’s global commercial organization, including sales, marketing and customer experience.

This innovation, along with the appointment of Jon Coleman as the Chief Commercial Officer, potentially bolstered investor confidence. Meanwhile, broader market trends showed a slight decline in ...

Managers Jonathan Coleman, Scott Stutzman, and Aaron Schaechterle search for competitively advantaged businesses that can grow throughout the economic cycle. Valuation is an important consideration.

If Jonathan Majors ever gets tired of being an A-list actor, weightlifting legend Ronnie Coleman tells TMZ Sports the dude could seriously be a pro bodybuilder!! Coleman made the proclamation in a sit ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility ...